Yahoo Finance

Vima Therapeutics Launches to Advance the First Oral Therapy for People with Dystonia and Related Movement Disorders

CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Vima Therapeutics, a clinical-stage biotechnology company focused on oral therapies for movement disorders, launched today with a $60M Series A ...
Yahoo Finance

Vima Therapeutics Announces First Dystonia Patient Dosed in Phase 2 Study and Extension of Series A to $100 Million to Advance Potential First-in-Class Oral Therapy for ...

CAMBRIDGE, Mass., March 11, 2026 (GLOBE NEWSWIRE)-- Vima Therapeutics, a clinical-stage biotechnology company focused on oral therapies for movement disorders, today announced the first person dosed ...
Mena FN

Vima Therapeutics Launches To Advance The First Oral Therapy For People With Dystonia And Related Movement Disorders

(MENAFN- GlobeNewsWire - Nasdaq) - $60 million Series A led by Atlas Venture, and founded by an expert team of physicians and scientists - VIM0423, a potential first-in-class oral medicine for ...
manilatimes

Vima Therapeutics Announces First Dystonia Patient Dosed in Phase 2 Study and Extension of Series A to $100 Million to Advance Potential First-in-Class Oral Therapy for ...

Phase 1 data in healthy volunteers and dystonia patients showed VIM0423 was safe and well-tolerated up to and exceeding target doses over 28 days CAMBRIDGE, Mass., March 11, 2026 (GLOBE NEWSWIRE)-- ...
manilatimes

Vima Therapeutics Launches to Advance the First Oral Therapy for People with Dystonia and Related Movement Disorders

- VIM0423, a potential first-in-class oral medicine for isolated dystonia, is currently being studied in a Phase 1 clinical trial; Phase 2 planned for fourth quarter of 2025 CAMBRIDGE, Mass., May 29, ...